Table 1.
Site of cancer and associated incidence rate of VTE among all cancer patients
| VTE (algorithm 1)# | VTE (algorithm 2)& | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total patient (n) | VTE cases (n) | Rate of VTE (%) | Observation time (p-y)a | Incidence of VTE (per 1,000 p-y) | VTE cases (n) | Rate of VTE (%) | Observation time (p-y)a | Incidence of VTE (per 1,000 p-y) | |
| All patients | 43,855 | 1,388 | 3.2 | 140,524 | 9.88 | 473 | 1.1 | 141,304 | 3.35 |
| Male | 23,115 | 896 | 3.9 | 66,063 | 13.56 | 259 | 1.1 | 66,571 | 3.89 |
| Female | 20,740 | 492 | 2.4 | 74,461 | 6.61 | 214 | 1.0 | 74,734 | 2.86 |
| Site of cancer | |||||||||
| Liver | 5,272 | 764 | 14.5 | 11,197 | 68.23 | 105 | 2.0 | 11,593 | 9.06 |
| Pancreas | 618 | 19 | 3.1 | 683 | 27.83 | 11 | 1.8 | 685 | 16.05 |
| Lung | 4,159 | 121 | 2.9 | 7,025 | 17.22 | 72 | 1.7 | 7,058 | 10.20 |
| Multiple myeloma | 183 | 4 | 2.2 | 375 | 10.65 | 3 | 1.7 | 379 | 7.92 |
| Non-Hodgkin’s lymphoma | 1,011 | 30 | 3.0 | 3,219 | 9.32 | 15 | 1.5 | 3,248 | 4.62 |
| Leukemia | 689 | 16 | 2.3 | 1,740 | 9.20 | 4 | 0.6 | 1,758 | 2.28 |
| Renal | 1,303 | 33 | 2.5 | 4,655 | 7.09 | 16 | 1.2 | 4,686 | 3.41 |
| Sarcoma | 458 | 12 | 2.6 | 1,761 | 6.82 | 9 | 2.0 | 1,773 | 5.08 |
| Stomach | 2,231 | 40 | 1.8 | 6,110 | 6.55 | 22 | 1.0 | 6,123 | 3.59 |
| Ovary | 668 | 15 | 2.3 | 2,390 | 6.28 | 11 | 1.7 | 2,405 | 4.57 |
| Colorectum | 6,462 | 112 | 1.7 | 22,452 | 4.99 | 69 | 1.1 | 22,502 | 3.07 |
| Esophageal | 761 | 6 | 0.8 | 1,239 | 4.84 | 4 | 0.5 | 1,240 | 3.23 |
| Brain | 522 | 7 | 1.3 | 1,559 | 4.49 | 5 | 1.0 | 1,562 | 3.20 |
| Endometrium and cervix | 2,327 | 43 | 1.9 | 10,024 | 4.29 | 31 | 1.3 | 10,055 | 3.08 |
| Prostate | 1,943 | 29 | 1.5 | 7,218 | 4.02 | 20 | 1.0 | 7,232 | 2.77 |
| Bladder | 1,723 | 23 | 1.3 | 6,477 | 3.55 | 14 | 0.8 | 6,484 | 2.16 |
| Testis | 119 | 2 | 1.7 | 582 | 3.44 | 0 | 0.00 | 590 | 0.00 |
| Other abdominal | 671 | 9 | 1.3 | 1,681 | 3.36 | 4 | 0.6 | 1,685 | 2.37 |
| Skin | 898 | 11 | 1.2 | 3,426 | 3.21 | 6 | 0.7 | 3,436 | 1.75 |
| Hodgkin’s lymphoma | 85 | 1 | 1.2 | 342 | 2.92 | 0 | 0.00 | 348 | 0.00 |
| Head and neck | 4,390 | 40 | 0.9 | 14,922 | 2.68 | 20 | 0.5 | 14,955 | 1.34 |
| Breast | 6,035 | 45 | 0.8 | 25,438 | 1.77 | 29 | 0.5 | 25,485 | 1.14 |
| Thyroid | 1,327 | 6 | 0.5 | 6,009 | 1.00 | 3 | 0.2 | 6,020 | 0.50 |
Abbreviations: p-y, person-years.
aFor VTE cases, person-years were calculated from index date to the date of first hospitalization for VTE during or after cancer diagnosis. For patients without VTE event, person-years were calculated from index date until end of follow-up date.
#VTE algorithm 1 was defined as a hospital admission with diagnostic codes of VTE (ICD-9-CM codes: 415.1x, 451.xx, 452, and 453.xx).
&VTE algorithm 2 was based on both the hospital admission with diagnostic codes of VTE and managements of VTE (prescription of intravenous or subcutaneous (IV/SC) anticoagulants (unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)) or reimbursement codes of surgical thromboectomy) during the hospital stay.